Safe, effective, short-term glucose control seen in MK-0941 users

12/1/2011 | PhysiciansBriefing.com

Type 2 diabetes patients on stable-dose insulin glargine who used the glucokinase inhibitor MK-0941 had better A1C and two-hour post-meal glucose levels at week 14, compared with those who took a placebo, according to a study in Diabetes Care. However, researchers found that such improvements in glycemic control were not sustained by 30 weeks.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI